Guardant Health, Inc. (NASDAQ:GH) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET

Company Participants

Alex Kleban - Vice President-Investor Relations

Helmy Eltoukhy - Chairman & Co-Chief Executive Officer

AmirAli Talasaz - Co-Chief Executive Officer

Mike Bell - Chief Financial Officer

Craig Eagle - Chief Medical Officer

Conference Call Participants

Dan Arias - Stifel

Puneet Souda - SVB Securities

Jack Meehan - Nephron Research

Kyle Mikson - Canaccord

Julia Qin - JPMorgan

Dave Delahunt - Golden Sachs.

Mark Massaro - BTIG

Tejas Savant - Morgan Stanley

Operator

Hello, and welcome to the Guardant Health First Quarter 2023 Financial Results Call. My name is Lauren and I will be coordinating your call today. [Operator Instructions] I will now hand you over to your host Alex Kleban, Vice President of Investor Relations to begin. Alex, please go ahead.

Alex Kleban

Thank you. Earlier today, Guardant Health released financial results for the quarter ended March 31, 2023. Joining me today from Guardant are Helmy Eltoukhy Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer. Craig Eagle, Guardant's Chief Medical Officer will join for Q&A.

Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.

This call will also include a discussion of non-GAAP financial measures are adjusted to exclude certain specified items. Additional information, regarding material risks and uncertainties, as well as reconciliations to the most directly comparable GAAP financial measures are available in the press release Guardant issued today, as well as in our Form 10-K and other filings with the SEC. Guardant disclaims any intention or obligation to update or revise financial projections and forward-looking statements, whether because of new information, future events or otherwise. Information in this conference call is accurate only as of the live broadcast.

With that I'd like to turn the call over to Helmy.

Helmy Eltoukhy

Thanks, Alex. Good afternoon, and thank you for joining our first quarter 2023 earnings call. I will start off today's call today for providing an update on our progress so far in 2023 and go into more detail on our progress in therapy selection and MRD. I will then turn the call over to AmirAli for an update on screening. And finally, Mike will provide a more detailed look at our financials and outlook for 2023.